The global health landscape is increasingly challenged by the soaring prevalence of obesity and Type 2 Diabetes, chronic conditions that demand innovative and effective treatment solutions. While lifestyle interventions remain foundational, pharmacological advancements are crucial to achieving sustained weight management and metabolic control. In this context, Cagrilintide, a groundbreaking long-acting amylin analog, represents a significant leap forward, particularly when co-administered with semaglutide as CagriSema.

Cagrilintide is an investigational novel acylated amylin analogue designed to act as a non-selective agonist for amylin receptors (AMYR) and calcitonin G protein-coupled receptors (CTR). Amylin, a hormone co-secreted with insulin by the pancreas, plays a vital role in slowing gastric emptying, reducing food intake, and regulating post-prandial glucose levels. Unlike first-generation amylin analogs like pramlintide, which require frequent dosing due to a short half-life, Cagrilintide features an N-terminal C20 fatty acid attachment, extending its half-life to approximately 7-8 days. This crucial modification enables convenient once-weekly subcutaneous administration, significantly enhancing patient adherence and therapeutic consistency.

Clinical trials have underscored Cagrilintide's efficacy as a standalone agent. In a Phase 2 trial involving individuals with overweight or obesity, Cagrilintide demonstrated dose-dependent and clinically meaningful weight loss, ranging from 6.0% to 10.8% over 26 weeks. Notably, the 4.5 mg dose of Cagrilintide exhibited superior weight reduction compared to liraglutide 3.0 mg (10.8% vs. 9.0%), highlighting its potent antiobesity effects.

The synergy between Cagrilintide and semaglutide, forming the combination therapy known as CagriSema, is particularly compelling. Semaglutide, a well-established GLP-1 receptor agonist, reduces appetite and improves glycemic control through distinct mechanisms. By combining Cagrilintide's amylin-mimetic actions with semaglutide's GLP-1 agonism, CagriSema leverages complementary pathways in the brain (hypothalamus and area postrema) and gut to achieve amplified therapeutic benefits. This dual action leads to a more profound reduction in hunger and food intake, alongside enhanced blood sugar regulation.

Early clinical data on CagriSema is highly promising. A Phase 1b trial showed substantial weight reductions of 15.7% (Cagrilintide 1.2 mg + semaglutide) and 17.1% (Cagrilintide 2.4 mg + semaglutide) over 20 weeks, surpassing the 9.8% observed with semaglutide alone. Furthermore, recent Phase 3 trials, REDEFINE 1 and REDEFINE 2, have reported even more impressive outcomes. In REDEFINE 1, patients with overweight or obesity and comorbidities achieved an average 20.4% body weight reduction over 68 weeks with CagriSema, compared to 14.9% with semaglutide alone. For patients with Type 2 Diabetes in REDEFINE 2, CagriSema led to a 13.7% weight loss, coupled with significant improvements in HbA1c levels. These results position CagriSema as a potential game-changer in metabolic disease management, offering a level of efficacy comparable to or even exceeding existing single-agent therapies.

Regarding safety, Cagrilintide and CagriSema are generally well-tolerated. Common adverse events primarily involve mild to moderate gastrointestinal symptoms such as nausea, constipation, and vomiting, which are consistent with other incretin-based therapies and often managed by gradual dose escalation. Injection site reactions have also been reported, typically mild and non-serious. The overall safety profile supports further clinical development of this powerful combination.

As a leading manufacturer and supplier of high-quality pharmaceutical raw materials, NINGBO INNO PHARMCHEM CO.,LTD. is dedicated to supporting the advancement of such critical therapies. We understand the urgent need for effective solutions in the fight against obesity and diabetes. For those looking to buy or purchase high-purity Cagrilintide raw material, or to inquire about price and availability, NINGBO INNO PHARMCHEM CO.,LTD. offers a reliable source for your research and development needs. This innovative treatment, with its compelling efficacy and convenient dosing, holds immense potential to bridge the treatment gap between lifestyle interventions and bariatric surgery, offering renewed hope for millions worldwide.